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Insulin-like growth factor 1 and insulin reduced the binding of iZSI-labelled epidermal growth factor (12SI-EGF) to Swiss 
3T3 cells by 15-20s at 37°C but not at 4°C. Scatchard analysis indicated that IGF-1 and insulin affected the higher- 
affinity component of EGF binding, an effect previously associated with the activation of protein kinase C. However, 
the inhibition of iZ51-EGF binding by IGF-1 and insulin was increased, not reduced, when the cells were treated with 
high concentrations of phorbol esters to down-modulate protein kinase C. We suggest that IGF-1 and insulin activate 
a protein kinase with similar or overlapping specificity to that of protein kinase C. 
Insulin-like growth factor 1; Insulin; Protein kinase C; Epidermal growth factor receptor 
1. INTRODUCTION 
Swiss mouse 3T3 fibroblasts provide a useful 
model for studies of cell proliferation, mechanisms 
of growth factor action, and interactions between 
the receptors for different growth factors [l]. A 
diverse group of mitogens for Swiss 3T3 cells 
stimulate the breakdown of PIP2 to IP3 and 
diacylglycerol [2,3]. Diacylglycerol is a potent ac- 
tivator of protein kinase C [4,5], and the mitogens 
that induce PIP2 breakdown stimulate several 
responses which can also be initiated by the activa- 
tion of protein kinase C by phorbol esters or ex- 
ogenous diacylglycerol. These include the 
phosphorylation of a protein of M, 80000 (‘80K 
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tetradecanoyl phorbol 13-acetate 
protein’) [6], and the phosphorylation of the EGF 
receptor on Thr654 [7,8] which reduces the affinity 
of the receptor for EGF and hence decreases the 
cellular binding of lz51-EGF [3,8-121. 
The IGFs and insulin are an important second 
group of mitogens for Swiss 3T3 cells, giving a 
marked synergistic stimulation of DNA synthesis 
when used in combination with other mitogens, in- 
cluding agents which stimulate PIP2 hydrolysis 
and/or activate protein kinase C [ 11. Furthermore, 
the component of mitogenic stimulation induced 
by insulin is not sensitive to the down-modulation 
of protein kinase C by chronic treatment with 
phorbol esters [13,14]. These results indicate that 
protein kinase C is not a principal mediator of the 
mitogenic actions of IGF-1 or insulin, but they do 
not preclude the possibility that IGF-1 or insulin 
might activate protein kinase C to a limited extent, 
as suggested for insulin in BC3H-1 cells 115,161. 
We have repeatedly observed that IGF-1 and in- 
sulin cause a small reduction in the binding of 12’IY 
EGF to Swiss 3T3 cells. Here, we characterize this 
effect and demonstrate that it is unlikely to be due 
to an activation of protein kinase C. 
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2. EXPERIMENTAL 
2.1. Materials 
Dulbecco’s modified Eagle’s medium, antibiotics, trypsin 
and newborn calf serum were obtained from Flow 
Laboratories. Genetically engineered [Thrs9]1GF-I (manufac- 
tured by Amgen), Nalz51, and [20(n)-3H]PDBu were obtained 
from Amersham International. Mouse EGF and “‘1-EGF 
(spec. act. 900 Ci/mmol) were prepared as in [17,18]. PDBu, 
TPA and porcine insulin were obtained from Sigma and 
bombesin was from Bachem (England). Peptide hormones and 
phorbol esters were stored frozen as concentrated stock solu- 
tions in 10 mM HCl and dimethyl sulphoxide respectively, and 
were diluted in binding medium immediately before use. The 
equivalent volume dilutions of dimethyl sulphoxide did not af- 
fect the binding of ‘251-EGF. 
2.2. Methods 
Stock cultures of Swiss 3T3 cells were maintained and pas- 
saged as described [IS]. For experimental use, cells were seeded 
into 24-well cluster trays or 35.mm dishes (Nunc) and grown for 
7-10 days, by which time they were confluent and quiescent. 
Cells in which protein kinase C had been down-modulated were 
obtained by adding 1 ,uM PDBu (or 200 nM TPA) to the culture 
medium for the last 48 h prior to the experiment. The cells were 
then washed three times at 37°C with binding medium [IS] 
before performing ‘251-EGF binding assays at 37°C (75 min, for 
maximal binding) or 4°C (150 min) as in [18,19]. Total and non- 
specific binding (in the presence of a 200-fold excess of unla- 
belled EGF) were about 4 and 0.2% respectively, of the total 
radioactivity. 
The binding of [3H]PDBu to Swiss 3T3 cells was performed 
by a method based on that in [20]. The cells were incubated for 
30 min at 37°C in binding medium [IS] with [‘H]PDBu at the 
concentrations shown in section 3, in the absence or presence of 
1 ,zM TPA to determine non-specific binding. At the end of the 
incubation the cells were washed three times with PBS (pH 7.4) 
at 4°C; the bound radioactivity was released using 0.1 M NaOH 
to solubilize the cells, mixed with acidified scintillation fluid 
and determined using a Packard scintillation counter. 
3. RESULTS 
When Swiss 3T3 cells were incubated at 37°C 
with IGF-1 (100 ng/ml) or insulin (lOpg/ml), the 
binding of “‘1-EGF was reduced to 82+2 or 
85 -t 2% respectively of control values (mean f SE, 
n = 10). Dose-response curves indicated that the 
maximal effect on “‘1-EGF binding was obtained 
at concentrations of insulin above 1 pug/ml and of 
IGF-1 greater than or equal to 100 ng/ml (not 
shown). In contrast to the effects observed at 
37°C IGF-I and insulin had no effect on the 
binding of ‘251-EGF to Swiss 3T3 cells incubated at 
4°C (fig.la), indicating that the inhibition at 37°C 
was indirect rather than competitive. 
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Fig 1 Inhibition of “‘1-EGF binding to Swiss 3T3 cells at 37 . 
and 4°C. (a) Cells were incubated at 37°C (open columns) or 
4°C (hatched columns) with “‘1-EGF (1 ng/ml) and the 
following additions: insulin, 10 pg/ml; IGF-1, 100 ng/ml; 
bombesin, 15 pM and 15 nM; TPA, 10 nM. The reduction of 
specific binding from that in control cells was then determined: 
mean + SE, n = 3. (b) Scatchard analysis of the binding of “‘I- 
EGF (0.1-50 ng/ml) at 37‘C in the absence (0) or presence (0) 
of insulin (lOpg/ml). At the end of the incubation a sample of 
supernatant was removed to determine the free “‘1-EGF, and 
the specific binding was then determined. Similar results were 
obtained in two other experiments using IGF-1 and insulin 
respectively. 
When the inhibitory effects of IGF-1 or insulin 
on 1251-EGF binding were measured as a function 
of ‘251-EGF concentration, the reduction in 
binding was greatest at low concentrations of 
ligand. Scatchard plots of the data (fig.lb and not 
shown) were consistent with a significant (p<O.OS) 
reduction in the number of higher-affinity recep- 
tors (Kd-4x lo-” M), with no significant 
changes in total number of receptors or affinity of 
either class of receptor. 
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The addition of bombesin or phorbol esters 
resulted in maximal inhibition of lz51-EGF binding 
of about 60 or 80-85%) respectively (figs 1,2), con- 
sistent with the large effect of these activators of 
protein kinase C on the higher-affinity component 
of iz51-EGF binding, demonstrated previously by 
Scatchard analysis [3,9,10]. The maximal inhibi- 
tion induced by IGF-1 or insulin was approximate- 
ly equal to that induced by up to 15 pM bombesin 
(fig.la), 60 pM TPA, or 0.5 nM PDBu (fig.2a). A 
plot of the specific binding of [3H]PDBu to Swiss 
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Fig.2. Inhibition of “‘1-EGF binding to Swiss 3T3 cells by 
phorbol esters, and the binding of [3H]phorbol dibutyrate to 
Swiss 3T3 cells. (a) Cells were incubated for 75 min at 37°C with 
“‘1-EGF (I ng/ml) and TPA (0) or PDBu (0) at the 
concentrations indicated. The reduction of specific binding 
from that in control cells was then determined: means of 
duplicates. The inhibition by insulin (lOpg/ml) and IGF-1 (100 
ng/ml) in the same experiment is also shown: mean k SE, n = 3. 
(b) Cells were incubated for 30 min at 37°C with t3H]PDBu at 
the concentrations indicated, and the specific binding was 
determined. 
Fig.3. Effect of protein kinase C down-modulation on the 
inhibition of “‘1-EGF binding to Swiss 3T3 cells. Untreated 
cells (open columns) and cells in which protein kinase C had 
been down-modulated as described in the text (hatched 
columns) were incubated for 75 min at 37’C with ‘*‘I-EGF 
(1 ng/ml) and the following additions: insulin, 10 gg/ml; 
IGF-1, 100 ng/ml; bombesin, 15 pM; TPA, 10 nM. The 
reduction of specific binding from that in control cells was then 
determined: mean & SE, n = 3. 
3T3 cells, assumed to represent binding to protein 
kinase C [4], is shown in fig.2b. The dose of PDBu 
(0.5 nM) which was equivalent o IGF-1 or insulin 
in its effect on 12?-EGF binding occupied less than 
2% of the maximum available protein kinase C. In 
contrast, maximally effective concentrations of 
bombesin had effects similar to concentrations of 
PDBu which occupied 20-30% of protein kinase 
C. 
The mechanism of IGF-1 or insulin action on 
12?-EGF binding could be dissociated from the ac- 
tivation of protein kinase C by the down- 
modulation of protein kinase C using prolonged 
pretreatment of the cells with high concentrations 
of phorbol esters. In such cells, the inhibitory ef- 
fects of bombesin or phorbol esters on ‘*‘I-EGF 
binding were substantially reduced (fig.3). In con- 
trast, the inhibitory effects of insulin or IGF-I ac- 
tually increased (fig.3) to a level greater than the 
residual inhibition by bombesin or TPA. 
4. DISCUSSION 
Several observations uggest hat IGF-1 and in- 
sulin do not activate protein kinase C in Swiss 3T3 
cells. IGF-1 and insulin synergise in mitogenic 
stimulation with agents that stimulate protein 
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kinase C [ 1,13,14]; insulin does not induce the 
phosphorylation of the 80K protein substrate for 
protein kinase C [6]; neither IGF-1 nor insulin in- 
creases the breakdown of PIP2 to IP3 and 
diacylglycerol which could activate protein kinase 
C [21,22], but they potentiate the bombesin- 
stimulated production of IP3 [21] whereas activa- 
tion of protein kinase C is inhibitory (231. If a sub- 
population of protein kinase C that is unusually 
resistant to down-modulation (as described in 
BC3H-1 cells [24]) mediates the effects of IGF-1 
and insulin on ‘251-EGF binding to Swiss 3T3 cells, 
then it is also unusual in not mediating an action 
of TPA on “‘1-EGF binding. It therefore seems 
more likely that the effects of IGF-1 and insulin on 
1251-EGF binding are mediated by a mechanism in- 
dependent of protein kinase C. 
Recently, it was shown that platelet-derived 
growth factor is able to inhibit 1251-EGF binding to 
cells in which protein kinase C has been down- 
modulated [25]. This response appeared not to be 
due to activation of any residual protein kinase C, 
but was mediated by another kinase which is able 
to phosphorylate the EGF receptor on Thr654. If 
the inhibition of 1251-EGF binding by IGF-1 and 
insulin reported here also proves to be associated 
with the phosphorylation of this residue, then this 
would suggest that in the cascade of phosphoryla- 
tion responses activated by different growth fac- 
tors through their receptor tyrosine kinases [26], 
there are protein kinases of similar or overlapping 
specificities to that of protein kinase C. Such a 
network of protein kinases would provide a 
mechanism for the convergence of different 
signalling systems onto the pathway of cellular ac- 
tivation. 
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